M&A Deal Summary |
|
|---|---|
| Date | 2018-02-01 |
| Target | Sanofi SA - Leukine |
| Sector | Life Science |
| Buyer(s) | Partner Therapeutics |
| Sellers(s) | Sanofi |
| Deal Type | Divestiture |
SEARCH BY
Partner Therapeutics is an integrated commercial stage biotech company focused on the development and commercialization of therapeutics that improve health and economic outcomes in the treatment of cancer. PTx's development focus spans the entire range of cancer therapy from primary treatments to supportive care. Partner Therapeutics is based in Lexington, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: France M&A | 1 of 1 |
| Year: 2018 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1994 |
| Sector | Life Science |
| Employees | 82,878 |
| Revenue | 44.3B EUR (2024) |
Sanofi is a French multinational pharmaceutical company. Sanofi was founded in 1994 and is based in Paris, France.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 15 |
| Sector: Life Science M&A | 5 of 8 |
| Type: Divestiture M&A Deals | 7 of 15 |
| Country: France M&A | 5 of 9 |
| Year: 2018 M&A | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-01-22 |
Bioverativ
Waltham, Massachusetts, United States Bioverativ, Inc. is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. |
Buy | $11.6B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-04-17 |
Zentiva
Prague, Czech Republic Zentiva is a generics pharmaceutical company, offering generic medicines across all key therapeutic areas. Zentiva is based in Prague, Czech Republic. |
Sell | €1.9B |
